Jill Feldman: The importance of focusing on the 3 P’s when discussing treatment options after a patient experiences progression on targeted therapy
Jill Feldman, Co-Founder of EGFR Resisters, posted on LinkedIn:
“It was an honor to collaborate with Dr. Deepa Rangachari, Dr. AJ Piper-Vallillo, and Dr. Hollis Viray on this article in JCO Oncology Grand Rounds Series.
This article highlights the importance of focusing on the 3 P’s when discussing treatment options after a patient experiences progression on targeted therapy.
- Personalization (molecular)
- Parsimony (financial)
- Partnership (patient preferences)
Why are the 3 P’s important?
Targeted therapies have brought new hope for people diagnosed with EGFR lung cancer, but the emotional rollercoaster of the lived experience is underestimated.
The juxtaposition of being diagnosed with a terminal illness, followed by the ‘good’ news of an approved targeted therapy – effective for an average of 19 months – is emotionally distressing and downright devastating. The promise of extended life is tainted with the harsh reality of inevitable disease progression, which is terrifying, particularly when a definitive, durable treatment is not readily available. Progression is a stark reminder that cancer is unpredictable and is intensified by the sobering realization that with each line of therapy, we are closer to exhausting our options.
The focus on personalization, parsimony, and partnership in managing progression in EGFR NSCLC is a patient-centered approach to precision medicine.”
View additional information.
Source: Jill Feldman/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023